Literature DB >> 15486850

Adverse reactions to voriconazole.

Aileen E Boyd1, Simon Modi, Susan J Howard, Caroline B Moore, Brian G Keevil, David W Denning.   

Abstract

Voriconazole is a new antifungal agent effective in the treatment of invasive aspergillosis. Interpatient variation in plasma concentrations is considerable--more than 100-fold. We describe 3 patients with diverse manifestations of toxicity (e.g., hallucinations, hypoglycemia, electrolyte disturbance, and pneumonitis) possibly attributable to high voriconazole concentrations. Measurement of plasma concentrations could be helpful in optimizing voriconazole dosages.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15486850     DOI： 10.1086/424662

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  51 in total

Review 1.  Pharmacokinetics of antifungal agents in children.

Authors:  Kevin Watt; Daniel K Benjamin; Michael Cohen-Wolkowiez
Journal:  Early Hum Dev       Date:  2011-02-01       Impact factor: 2.079

2.  Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma.

Authors:  Lorena Baietto; Antonio D'Avolio; Giusi Ventimiglia; Francesco Giuseppe De Rosa; Marco Siccardi; Marco Simiele; Mauro Sciandra; Giovanni Di Perri
Journal:  Antimicrob Agents Chemother       Date:  2010-06-07       Impact factor: 5.191

3.  Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients.

Authors:  Maud Berge; Romain Guillemain; David A Trégouet; Catherine Amrein; Veronique Boussaud; Patrick Chevalier; Agnes Lillo-Lelouet; Christine Le Beller; Pierre Laurent-Puig; Philippe H Beaune; Eliane M Billaud; Marie-Anne Loriot
Journal:  Eur J Clin Pharmacol       Date:  2010-10-31       Impact factor: 2.953

4.  Does one voriconazole breakpoint suit all Candida species?

Authors:  Maiken Cavling Arendrup; David W Denning; M A Pfaller; D J Diekema; J H Rex
Journal:  J Clin Microbiol       Date:  2007-06       Impact factor: 5.948

5.  Concentrations of voriconazole in healthy and inflamed lung in rats.

Authors:  Christian Joukhadar; Christiane Thallinger; Wolfgang Pöppl; Florian Kovar; Karl H Konz; Samir M Joukhadar; Friederike Traunmüller
Journal:  Antimicrob Agents Chemother       Date:  2009-03-30       Impact factor: 5.191

Review 6.  Antifungal therapeutic drug monitoring: established and emerging indications.

Authors:  David Andes; Andres Pascual; Oscar Marchetti
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

7.  What is the role of therapeutic drug monitoring in antifungal therapy?

Authors:  Jeannina A Smith
Journal:  Curr Infect Dis Rep       Date:  2009-11       Impact factor: 3.725

8.  Therapeutic drug monitoring in voriconazole-associated hyponatremia.

Authors:  Ren-Ai Xu; Shuang-Li Zheng; Li-Li Xiao; Xue-Ding Cai; Xi-Xi Lai; Guan-Yang Lin; Lu-Feng Hu; Chun-Hong Zhang; Zhi-Sheng Xu; Xiu-Hua Zhang
Journal:  Med Mycol Case Rep       Date:  2013-06-19

9.  Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome.

Authors:  Gloria N Mattiuzzi; Jorge Cortes; Gladys Alvarado; Srdan Verstovsek; Charles Koller; Sherry Pierce; Deborah Blamble; Stefan Faderl; Lianchun Xiao; Mike Hernandez; Hagop Kantarjian
Journal:  Support Care Cancer       Date:  2009-12-03       Impact factor: 3.603

Review 10.  [Update: invasive fungal infections: Diagnosis and treatment in surgical intensive care medicine].

Authors:  C Lichtenstern; S Swoboda; M Hirschburger; E Domann; T Hoppe-Tichy; M Winkler; C Lass-Flörl; M A Weigand
Journal:  Anaesthesist       Date:  2010-01       Impact factor: 1.041
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.